Patents Assigned to Quintessence Biosciences, Inc.
  • Therapeutic ribonucleases
    Patent number: 9579365
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: February 28, 2017
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Non-natural ribonuclease conjugates as cytotoxic agents
    Patent number: 9393319
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: July 19, 2016
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Methods and compositions for the treatment of cancer
    Patent number: 9192656
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 24, 2015
    Assignee: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: John A Kink, Laura E. Strong, Mark N. Shahan
  • Therapeutic ribonucleases
    Patent number: 9006407
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 14, 2015
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Modified ribonucleases
    Patent number: 8840882
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: September 23, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: John A. Kink, Laura E. Strong, Vladimir Trubetskoy, Mark N. Shahan
  • NON-NATURAL RIBONUCLEASE CONJUGATES AS CYTOTOXIC AGENTS
    Publication number: 20140212946
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Application
    Filed: April 14, 2014
    Publication date: July 31, 2014
    Applicant: Quintessence Biosciences, Inc.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20140128457
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: January 7, 2014
    Publication date: May 8, 2014
    Applicant: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Non-natural ribonuclease conjugates as cytotoxic agents
    Patent number: 8697065
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: April 15, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Compositions and methods for ribonuclease-based therapeutics
    Patent number: 8697062
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: April 15, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Ronald T. Raines, Thomas J. Rutkoski, John A. Kink, Laura E. Strong
  • NON-NATURAL RIBONUCLEASE CONJUGATES AS CYTOTOXIC AGENTS
    Publication number: 20140017241
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Application
    Filed: June 20, 2013
    Publication date: January 16, 2014
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • Therapeutic ribonucleases
    Patent number: 8628768
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: January 14, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Non-natural ribonuclease conjugates as cytotoxic agents
    Patent number: 8470315
    Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: June 25, 2013
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20120276077
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: July 10, 2012
    Publication date: November 1, 2012
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Methods and compositions for the treatment of cancer
    Patent number: 8298801
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: October 30, 2012
    Assignee: Quintessence Biosciences, Inc.
    Inventors: John A. Kink, Laura E. Strong, Mark N. Shahan
  • Therapeutic ribonucleases
    Patent number: 8216567
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: July 10, 2012
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20120003150
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: September 13, 2011
    Publication date: January 5, 2012
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Therapeutic ribonucleases
    Patent number: 8029782
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: October 4, 2011
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20100080789
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: October 1, 2009
    Publication date: April 1, 2010
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Tony Klink, John Kink, Laura Strong
  • COMPOSITIONS AND METHODS FOR RIBONUCLEASE-BASED THERAPEUTICS
    Publication number: 20090098101
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Application
    Filed: October 8, 2008
    Publication date: April 16, 2009
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Ronald T. Raines, Thomas J. Rutkoski, John A. Kink, Laura E. Strong
  • Methods and compositions for the treatment of cancer
    Publication number: 20080095755
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Application
    Filed: July 17, 2007
    Publication date: April 24, 2008
    Applicant: Quintessence Biosciences, Inc.
    Inventors: John Kink, Laura Strong, Mark Shahan